Rebecca M Hluhanich

Pharmacist intervention lowers HgbA1c in diabetic patients regardless of HIV status

Machelle D. Wilson, N. Nelson, Jeffrey R Fine, 2021, Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia.

Comparing Hepatitis C Virus Screening in Clinics Versus the Emergency Department

L. May, S. Sarkar, J. Ford, 2022, The western journal of emergency medicine.

Preclinical and Clinical Profile of HIV-1 Integrase Strand-transfer InhibitorGS-9224 Compared to its Parent Compound GS-9160

Gregg S. Jones, Jim Zheng, Rebecca M Hluhanich, 2014 .

Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.

Wei Huang, M. Balakrishnan, T. Kirschberg, 2008, Bioorganic & medicinal chemistry letters.

The Combined Anti-HIV-1 Activities of Emtricitabine and Tenofovir plus the Integrase Inhibitor Elvitegravir or Raltegravir Show High Levels of Synergy In Vitro

K. White, Rebecca M Hluhanich, M. Miller, 2014, Antimicrobial Agents and Chemotherapy.

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

K. White, M. Tsiang, Gregg S. Jones, 2012, Antiviral research.

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

K. White, Xiaowu Chen, E. Svarovskaia, 2013, Antimicrobial Agents and Chemotherapy.

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents

M. Corwin, B. Durbin-Johnson, S. Sarkar, 2018, Hepatic oncology.

hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.

M. Corwin, B. Durbin-Johnson, S. Sarkar, 2018 .

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

K. White, M. Tsiang, Gregg S. Jones, 2012, Antiviral research.